Blog

Cristian Massacesi: Very much enjoyed being part of the Endpoints panel at ASCO2024

Photo taken from Cristian Massacesi/LinkedIn

Jun 11, 2024, 11:49

Cristian Massacesi: Very much enjoyed being part of the Endpoints panel at ASCO2024

Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer at AstraZeneca, posted on LinkedIn:

“Very much enjoyed being part of the Endpoints panel at ASCO2024. Alongside Julie Gralow, Timothy A. Yap and Kyle LaHucik, we reviewed the major scientific breakthroughs from this year’s conference and how these advances could potentially translate into improved outcomes for patients.

Themes from the discussion close to my heart included:

How the deeper convergence of science, data and technology can support smarter and faster decision-making in discovery and development.
How to further enhance precision medicine and better, targeted treatments in oncology, with great focus on how to improve and manage toxicities.
Exciting progress with new, disruptive modalities and the opportunities for combinations to offer even more transformational cancer regimens.
The growth in antibody drug conjugates and how they can be best sequenced across different disease settings for maximum impact.

Another excellent ASCO on many levels. There’s certainly never been a more exciting time to be working in oncology.”

Cristian Massacesi

Source: Cristian Massacesi/LinkedIn
.

Antibody drug conjugates ASCO2024 AstraZeneca cancer cancer regimen transformation combination therapies Cristian Massacesi data utilization disease sequencing disruptive modalities Endpoints panel OncoDaily Oncology oncology advancements oncology progress patient outcomes Precision Medicine science convergence scientific breakthroughs targeted treatments technology integration Toxicity management

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage